Icahn snaps up more of Biogen

The Biogen Idec faithful have been preaching "buying opportunity" ever since the company announced two new cases of the brain infection that can afflict patients taking its vaunted multiple sclerosis drug Tysabri. After all, CEO James Mullen had warned that the potentially fatal malady, PML, could and would crop up again, and the MS sufferers taking the drug have been made fully aware of the risk.

We can now count Carl Icahn among those faithful. The activist investor has taken this opportunity to boost his stake in Biogen to 6 percent from about 4.3 percent. That's a $259 million investment.

What's next, given that Icahn rarely puts his money where his mouth won't go? According to SEC documents, he may talk to the company about "concerns relating to shareholder value." Hmm. You'll recall that Icahn recently pressured Biogen into putting itself up for sale, and then accused management sandbagging the bidding process. Perhaps another round of bids is in Biogen's future.

- read the post at the Wall Street Journal Health Blog
- see the item at StreetInsider

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.